目的 探讨不同分子亚型乳腺癌骨转移患者的临床病理特征及预后.方法 收集2007年9月1日至2011年9月1日于西安交通大学第一附属医院诊治的300例乳腺癌骨转移患者资料,回顾性分析其临床特征及预后.结果 Luminal A型、Luminal B型、Her-2过表达型以及三阴性乳腺癌在本组乳腺癌骨转移患者(300例)中所占比率分别为59.0％、16.0％、13.7％和11.3％.4组患者在年龄、原发肿瘤大小和组织学分级方面的差异具有统计学意义(P<0.05),而绝经状态、淋巴结转移、病理类型及脉管侵犯等指标差异均无统计学意义(P>0.05).Kaplan-Meier生存分析显示,Luminal A型乳腺癌骨转移患者的中位生存时间为28.6月,高于Luminal B型(26.9月)、Her-2过表达型(20.9月)及三阴性(12.0月)乳腺癌骨转移患者.4组患者的总生存时间差异有统计学意义(P<0.05).结论 不同亚型乳腺癌骨转移患者的临床特征和预后存在差异;Lumina A型乳腺癌骨转移患者预后较好,三阴性乳腺癌骨转移患者预后较差.%Objective To analyze the clinicopathological characteristics and prognosis of different subtypes of breast cancer patients with bone metastasis.Methods For this study, we recruited 300 primary breast cancer patients with bone metastasis treated at the Department of Oncology, the First Affiliated Hospital of Xi`an Jiaotong University, between September 1, 2007 and September 1, 2011.We also retrospectively analyzed their clinical and follow-up data.Results The percentage of Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER-2) overexpression and triple negative subtypes in all the bone metastatic breast cancer patients was 59.0％, 16.0％, 13.7％ and 11.3％, respectively.Age, tumor size and histologic grade significantly differed among the four subtypes (P<0.05).However, there were no significant differences in menopausal status, lymph node metastasis, histological type or lymphovascular invasion among different subtypes (P>0.05).The median survival time of Luminal A breast cancer patients with bone metastasis was 28.6 months, longer than Luminal B (26.9 months), HER-2 overexpression (20.9 months) and triple negative breast cancer patients (12.0 months) with bone metastasis.The overall survival significantly differed among the patients with four subtypes of breast cancer.Conclusion Different subtypes of breast cancer patients with bone metastasis have different clinical characteristics and prognosis.Luminal A breast cancer patients with bone metastasis have better prognosis whereas triple negative subtype has poorer prognosis.
展开▼
